Changing the course of immune-related diseases and ageing.

Immunis is a private biotechnology company researching and developing immune secretome products to address age-driven immune deficits. Immunis developed a novel method to isolate clinical-grade, secreted cellular factors with immune modulating capabilities that can benefit immune system health and development. With age, every person experiences an imbalance in the beneficial secreted factors and our technology replenishes them. Immunis' first clinical trial is a Phase 1/2a study of the safety and tolerability of IMMUNA for elderly individuals who have muscle atrophy associated with knee osteoarthritis. Preclinical data supports that IMMUNA promotes muscle regeneration and benefits metabolism.